
==== Front
Appl. Biochem. Microbiol
Applied Biochemistry and Microbiology
0003-6838 1608-3024 SP MAIK Nauka/Interperiodica Dordrecht 

6218
10.1134/S0003683810090024
Article
Progress in the development of pandemic influenza vaccines and their production technologies
Kiselev O. I. office@influenza.spb.ru  grid.466123.4Research Institute of Influenza, North Western Division, Russian Academy of Medical Sciences (RAMS), St. Petersburg, 197376 Russia 
12 11 2010 
2010 
46 9 815 830
27 1 2010 © Pleiades Publishing, Ltd. 2010This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.This article analyzes the current situation in the field of construction and production of pandemic influenza vaccines. The main task of protecting the population against influenza pandemics requires state-of-the-art approaches to the construction of influenza vaccines to be based on reassortment and genetic engineering techniques, including the analysis of primary structures of influenza viral genes, synthesis and cloning of the main viral genes, reverse genetics techniques, and banks of plasmids bearing basic viral genes. Reassortant technologies are now giving way to new approaches for objective reasons. The state-of-the-art technologies provide safety not only at the laboratories where vaccine viruses are constructed but also make the production process wholly safe. We are using the following approaches to the development of industrial production: use of nanoparticles and nanoemulsions as functional adjuvants, construction of totally-safe strains for live attenuated influenza vaccines with deletions of molecular determinants of pathogenicity, application of protein and chemical chaperones to provide self-assembly of haemagglutinin molecules of the H1N1v-2009 virus, and impregnation of whole-virion preparations with nanoparticles to enhance antigenicity.

Key words
adjuvantsantigensvaccinesviral proteinsvirus-like particleslive attenuated vaccinesreplication-deficient vaccinesissue-copyright-statement© Pleiades Publishing, Ltd. 2010
==== Body
Abbreviations
WHOWorld Health Organization

VLPviruslike particles

LAIVlive attenuated influenza vaccine

IIVinactivated influenza vaccine

RNPribonucleoproteide

WVPwhole-virion preparations

FDAFood and Drug Administration

HAhaemagglutinin

Original Russian Text © O.I. Kiselev, 2010, published in Biotekhnologiya, 2010, No. 2, pp. 8–24.
==== Refs
References
1. Pokrovskii V.I.  Kiselev O.I.   Gripp ptits: proiskhozhdenie infektsionnykh biokatastrof 2005 St. Petersburg Rostok 
2. Deeva E.G.   Gripp. Na poroge pandemii 2008 Moscow Geotar 
3. Aleksandrova, G.I., in Trudy instituta eksperimental’noi meditsiny AMN SSSR. “Etiologiya, immunologiya i klinika aziatskogo grippa” (Transactions of the Institute of Experimental Medicine, Academy of Medical Sciences of the USSR Etiology, Immunology, and Clinics of Asian Influenza), Leningrad, 1961, pp. 154–161.
4. Gendon, M.Yu., Vopr. Virusol., 2004, no. 4, pp. 4–12.
5. Zhdanov V.M.  Antonov I.V.   Byull. VOZ. Gripp Gonkong. Mezhdunarodnaya konferentsiya 1969 41 392 397 
6. Ivannikov, Yu.G. and Ismagulov, A.G., Epidemiologiya grippa (Influenza Epidemiology), Alma-Ata, 1983.
7. Kiselev O.I.  Tsybalova L.M.  Pokrovskii V.I.   Zh. Mikrobiol. Epidemiol. Immunobiol. 2006 5 28 38 16981491 
8. Murrei R.   Byull. VOZ. Gripp Gonkong. Mezhdunarodnaya Konferentsiya 1969 41 509 511 
9. Gendon, Yu.Z., Vopr. Virusol., 2001, no. 3, pp. 5–12.
10. Gendon, Yu.Z., Vopr. Virusol., 2002, no. 6, pp. 4–11.
11. Gendon, Yu.Z., Vopr. Virusol., 2007, no. 1, pp. 4–10.
12. Pokrovskii V.I.  Kiselev O.I.   Pandemiya-2009. Novyi virus H1N1 2009 St. Petersburg Rostok 
13. European Committee for Proprietary Medicinal products. Note for Guidance on Harmonization of Requirements for Influenza Vaccines. 1997 (COMP/BWP/214/96). European Agency for the Evaluation of Medicinal Products, March 12, 1997.
14. Kiselev, O.I., Skryabin, K.G., and Ravvin, N.V., RF Patent No. 2 358 981, 2009.
15. Bresson J.-L.  Perrone C.  Launay O.   The Lancet 2006 367 1657 1664 10.1016/S0140-6736(06)68656-X 
16. Stephenson I.  Gust I.  Kieny M.P.  Pervikov I.   Lancet. D 2006 6 71 72 10.1016/S1473-3099(06)70364-4 
17. Racaniello V.R.  Baltimore D.   Science 1981 214 916 919 10.1126/science.6272391 6272391 
18. Pleschka S.  Jaskunas R.  Engelhardt O.G.   J. Virol. 1996 70 4188 4192 8648766 
19. Garcia-Sastre  Egorov A.  Matassov D.   Virology 1998 252 324 330 10.1006/viro.1998.9508 9878611 
20. Wood G.M.   Phil. Trans. R. Soc. Lond. B 2001 356 1953 1960 10.1098/rstb.2001.0981 11779397 
21. WHO (World Health Organization). 2005. WHO Guidance on Development of Influenza Vaccine Reference Viruses by Reverse Genetics. Available online at http://www.who.int/csr/resources/publication/influenza/WHO_CDS_CSR_GIP_2005_6.pdf.
22. Romanova, J., Krenn, B.M., and Wolschek, M., PLoS ONE, 2009, vol. 4, no. 6.
23. Hickling J.  D’Hondt E.   A Review of Production Technologies for Influenza Virus Vaccines and Their Suitability for Deployment in Developing Countries for Influenza Pandemic Preparedness. World Health Organization Initiative for Vaccine Research 2006 Genewa Switzerland 
24. Stukova M.A.  Sereinig S.  Zabolotnyh N.V.  Ferko B.  Kittel C.  Romanova J.  Vinogradova T.I.  Katinger H.  Kiselev O.I.  Egorov A.   Tuberculosis (Edinb.) 2006 86 236 246 10.1016/j.tube.2006.01.010 16677861 
25. Kost, T.A., Condreay, J.P., and Jarvis, D.L., Nature Biotechnol., 2005, vol. 23.
26. Nochi T.  Takagi H.  Yuki Y.   Proc. Natl. Acad. Sci. USA 2007 104 10986 10991 10.1073/pnas.0703766104 17573530 
27. Fiers W.  De Filette M.  Birkett A.   Virus Research 2004 103 173 176 10.1016/j.virusres.2004.02.030 15163506 
28. Neirynck S.  Deroo T.  Saelens X.   Nature Medicine 1999 5 1157 1163 10.1038/13484 10502819 
29. Geeraeds, F., Goutagny, N., and Hornung, V., PLoS Pathol., 2008, no. 4.

